Table 4.
TPE indications and outcomes.
| TPE indication/Outcome | Improvement, N. patients (%) | Unchanged, N. patients (%) | Worsening, N. patients (%) | Total | Death, N. patients (%) | Dialysis |
|---|---|---|---|---|---|---|
| DAH | 11 (55) | 2 (10) | 7 (35) | 20 | 7 (35) | 3 (15) |
| Neuropsychiatric SLE | 7 (78) | 1 (11) | 1 (11) | 9 | 1 (11) | 1 (11) |
| RPGN | 5 (71) | 2 (29) | 0 | 7 | 0 | 3 (60) |
| CAPS | 4 (80) | 0 | 1 (20) | 5 | 1 (20) | 0 |
| Thrombotic microangiopathy | 2 (40) | 1 (20) | 2 (40) | 5 | 2 (40) | 1 (20) |
| Lupus Nephritis | 2 (50) | 2 (50) | 0 | 4 | 0 | 2 (50) |
| Lupus severe skin involvement | 3 (100) | 0 | 0 | 3 | 0 | 0 |
| Inflammatory myopathies | 1 (33) | 1 (33) | 1 (33) | 3 | 1 (33) | 0 |
| Optic Neuromyelitis | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| Severe scleroderma | 0 | 1 (100) | 0 | 1 | 0 | 0 |
| Evans Syndrome | 0 | 1 (100) | 0 | 1 | 0 | 0 |
| Insulin resistance type B | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| Legs vasculitis | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| CNS Vasculitis | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| Gastrointestinal lupus | 0 | 1 (100) | 0 | 1 | 0 | 0 |
| Autoimmune meningoencephalitis | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| Severe SLE | 1 (100) | 0 | 0 | 1 | 0 | 0 |
| Acute allograft rejection | 0 | 1 (100) | 0 | 1 | 0 | 1 (100) |
TPE: therapeutic plasma exchange; DAH: diffuse alveolar hemorrhage; SLE: systemic lupus erythematosus; RPGN: rapidly progressive glomerulonephritis CAPS: catastrophic antiphospholipid syndrome; CNS: central nervous system.